Health Canada approves Pfizer's gene therapy for treatment of hemophilia
CBC
Pfizer said on Wednesday that Canada's health regulator approved its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B ahead of a U.S. decision.
The approval was based on late-stage trials that showed a single dose of the therapy, to be sold under the brand name Beqvez, was superior to the current standard of care which involves replacing a blood-clotting protein called factor IX, according to the company's release.
The therapy is for patients over 18 living with moderately severe to severe hemophilia B.
The U.S. Food and Drug Administration (FDA) had in November 2022 approved pharmaceutical company CSL's product Hemgenix, making it the first one-time gene therapy for hemophilia B.
CSL had acquired exclusive global rights to Hemgenix from gene therapy maker uniQure NV in 2021.
Pfizer is also seeking U.S. approval for its experimental antibody, marstacimab, to treat hemophilia A and B.
Beqvez is listed as an approved product on Health Canada's online database. CBC News reached out to Health Canada for comment on Pfizer's announcement.
Hemophilia is a hereditary condition in which blood does not clot normally, according to the Canadian Hemophilia Society. Patients who have the condition bleed spontaneously, excessively or for a longer time than is typical.
Hemophilia B is found in 1 in 40,000 people and represents about 15 per cent of patients with hemophilia, according to the FDA.
The U.S. health regulator is expected to give its decision on Pfizer's therapy in the second quarter of 2024.
If it weren't for a stem cell transplant — less than half a cup of blood from a stranger's umbilical cord — four-year-old Tristan Ford would almost certainly have died as an infant, his parents say.
A Métis saddle from the early 1800s is at the centre of an exhibit that opened last month at a Swiss museum, along with contemporary beadwork created by other Red River Métis artists.
A dome-shaped device floating in Halifax's Northwest Arm could easily be confused with a buoy, but it is actually a contraption meant to turn ocean water into fresh water.
As of Tuesday, there are limits on the number of bottles of spirits a person can buy at the B.C. Liquor store in Tofino, a move that leaders of the Ahousaht First Nation were pushing for.
This story is part of CBC Health's Second Opinion, a weekly analysis of health and medical science news emailed to subscribers on Saturday mornings. If you haven't subscribed yet, you can do that by clicking here.
Mohawk code talkers and their missions were so vital during the Second World War, that some believe without them, there was no way of winning of the war.
Two feisty ferret babies in Virginia are being hailed as a symbol of hope for the future of their species.
On day one of Donald Trump's presidency, Robert F. Kennedy Jr. says he'll be advising Trump to take fluoride out of public water. The former independent presidential hopeful — and prominent proponent of debunked public health claims — has been told he'll be put in charge of health initiatives in the new Trump administration. He's described fluoride as "industrial waste."
An RCMP national security unit monitored First Nations-led anti-pipeline activism for "potential threats" to the energy, transportation and banking sectors between 2021 and 2022, internal police documents show.
WARNING: this story contains details of cultural items being forcibly removed
Rachelle and Kelly Swan live in a relatively cramped space now. But the upside to their rented low-income government house is that it's away from the haunting site their family occupied for two years, filled with screeches, high-pitched chirps and squeaks from constantly flapping bats.